Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): Cardiovascular implications

Jason B. Lindsey, Francesco Cipollone, Shuaib M Abdullah, Darren K McGuire

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Disorders of glucose metabolism are associated with increased risk for cardiovascular disease (CVD) complications, including coronary, peripheral and cerebral arterial disease, that account for the majority of morbidity and mortality among patients with diabetes mellitus (DM). These associations between glucose and CVD risk extend continuously well below the glycaemic thresholds established for the diagnosis of diabetes, including significantly increased risk associated with impaired fasting glucose, impaired glucose tolerance, and even high normal glucose concentrations. While these epidemiological observations have established a clear association between cardiovascular disease and dysglycaemia and suggest a direct causal link, the mechanisms by which hyperglycaemia may contribute to the development, progression and instability of atherosclerosis remain unclear. A number of recent advances in the realm of vascular biology have identified several novel, plausible pathways that might link hyperglycaemia with atherosclerosis, individually or in aggregate. Key among them are the interaction between advanced glycation end-products (AGEs) and the receptor for AGEs (RAGE), which exists as a trans-membrane signalling receptor and as a circulating form, soluble RAGE (sRAGE). The purpose of this review is to provide an overview of the present understanding of RAGE and sRAGE, their plausible role linking perturbed glucose metabolism with the development, progression and instability of atherosclerosis, and the potential therapeutic implications of modulation of this biological system.

Original languageEnglish (US)
Pages (from-to)7-14
Number of pages8
JournalDiabetes and Vascular Disease Research
Volume6
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint

Glucose
Atherosclerosis
Cardiovascular Diseases
Hyperglycemia
Cerebral Arterial Diseases
Glucose Metabolism Disorders
Advanced Glycosylation End Products
Glucose Intolerance
Peripheral Arterial Disease
Blood Vessels
Fasting
Diabetes Mellitus
Morbidity
Membranes
Mortality
Advanced Glycosylation End Product-Specific Receptor
Therapeutics

Keywords

  • Advanced glycation end products
  • Atherosclerosis
  • Diabetes
  • Hyperglycaemia
  • Receptor for advanced glycation end products

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE) : Cardiovascular implications. / Lindsey, Jason B.; Cipollone, Francesco; Abdullah, Shuaib M; McGuire, Darren K.

In: Diabetes and Vascular Disease Research, Vol. 6, No. 1, 01.2009, p. 7-14.

Research output: Contribution to journalArticle

@article{40944d8fd13d48ee89907bfc4b8e06f8,
title = "Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): Cardiovascular implications",
abstract = "Disorders of glucose metabolism are associated with increased risk for cardiovascular disease (CVD) complications, including coronary, peripheral and cerebral arterial disease, that account for the majority of morbidity and mortality among patients with diabetes mellitus (DM). These associations between glucose and CVD risk extend continuously well below the glycaemic thresholds established for the diagnosis of diabetes, including significantly increased risk associated with impaired fasting glucose, impaired glucose tolerance, and even high normal glucose concentrations. While these epidemiological observations have established a clear association between cardiovascular disease and dysglycaemia and suggest a direct causal link, the mechanisms by which hyperglycaemia may contribute to the development, progression and instability of atherosclerosis remain unclear. A number of recent advances in the realm of vascular biology have identified several novel, plausible pathways that might link hyperglycaemia with atherosclerosis, individually or in aggregate. Key among them are the interaction between advanced glycation end-products (AGEs) and the receptor for AGEs (RAGE), which exists as a trans-membrane signalling receptor and as a circulating form, soluble RAGE (sRAGE). The purpose of this review is to provide an overview of the present understanding of RAGE and sRAGE, their plausible role linking perturbed glucose metabolism with the development, progression and instability of atherosclerosis, and the potential therapeutic implications of modulation of this biological system.",
keywords = "Advanced glycation end products, Atherosclerosis, Diabetes, Hyperglycaemia, Receptor for advanced glycation end products",
author = "Lindsey, {Jason B.} and Francesco Cipollone and Abdullah, {Shuaib M} and McGuire, {Darren K}",
year = "2009",
month = "1",
doi = "10.3132/dvdr.2009.002",
language = "English (US)",
volume = "6",
pages = "7--14",
journal = "Diabetes and Vascular Disease Research",
issn = "1479-1641",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE)

T2 - Cardiovascular implications

AU - Lindsey, Jason B.

AU - Cipollone, Francesco

AU - Abdullah, Shuaib M

AU - McGuire, Darren K

PY - 2009/1

Y1 - 2009/1

N2 - Disorders of glucose metabolism are associated with increased risk for cardiovascular disease (CVD) complications, including coronary, peripheral and cerebral arterial disease, that account for the majority of morbidity and mortality among patients with diabetes mellitus (DM). These associations between glucose and CVD risk extend continuously well below the glycaemic thresholds established for the diagnosis of diabetes, including significantly increased risk associated with impaired fasting glucose, impaired glucose tolerance, and even high normal glucose concentrations. While these epidemiological observations have established a clear association between cardiovascular disease and dysglycaemia and suggest a direct causal link, the mechanisms by which hyperglycaemia may contribute to the development, progression and instability of atherosclerosis remain unclear. A number of recent advances in the realm of vascular biology have identified several novel, plausible pathways that might link hyperglycaemia with atherosclerosis, individually or in aggregate. Key among them are the interaction between advanced glycation end-products (AGEs) and the receptor for AGEs (RAGE), which exists as a trans-membrane signalling receptor and as a circulating form, soluble RAGE (sRAGE). The purpose of this review is to provide an overview of the present understanding of RAGE and sRAGE, their plausible role linking perturbed glucose metabolism with the development, progression and instability of atherosclerosis, and the potential therapeutic implications of modulation of this biological system.

AB - Disorders of glucose metabolism are associated with increased risk for cardiovascular disease (CVD) complications, including coronary, peripheral and cerebral arterial disease, that account for the majority of morbidity and mortality among patients with diabetes mellitus (DM). These associations between glucose and CVD risk extend continuously well below the glycaemic thresholds established for the diagnosis of diabetes, including significantly increased risk associated with impaired fasting glucose, impaired glucose tolerance, and even high normal glucose concentrations. While these epidemiological observations have established a clear association between cardiovascular disease and dysglycaemia and suggest a direct causal link, the mechanisms by which hyperglycaemia may contribute to the development, progression and instability of atherosclerosis remain unclear. A number of recent advances in the realm of vascular biology have identified several novel, plausible pathways that might link hyperglycaemia with atherosclerosis, individually or in aggregate. Key among them are the interaction between advanced glycation end-products (AGEs) and the receptor for AGEs (RAGE), which exists as a trans-membrane signalling receptor and as a circulating form, soluble RAGE (sRAGE). The purpose of this review is to provide an overview of the present understanding of RAGE and sRAGE, their plausible role linking perturbed glucose metabolism with the development, progression and instability of atherosclerosis, and the potential therapeutic implications of modulation of this biological system.

KW - Advanced glycation end products

KW - Atherosclerosis

KW - Diabetes

KW - Hyperglycaemia

KW - Receptor for advanced glycation end products

UR - http://www.scopus.com/inward/record.url?scp=59149100896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59149100896&partnerID=8YFLogxK

U2 - 10.3132/dvdr.2009.002

DO - 10.3132/dvdr.2009.002

M3 - Article

C2 - 19156622

AN - SCOPUS:59149100896

VL - 6

SP - 7

EP - 14

JO - Diabetes and Vascular Disease Research

JF - Diabetes and Vascular Disease Research

SN - 1479-1641

IS - 1

ER -